Biphasic Fever (Dengue): A Comprehensive Medical Guide
Overview
Biphasic fever refers to a characteristic pattern of temperature rise, temporary defervescence (a period of normal temperature), and then a second rise in fever. In the context of dengue infection, this pattern is classic for Dengue Fever, a mosquito‑borne viral illness caused by one of four Dengue virus serotypes (DEN‑1 to DEN‑4).
Dengue is endemic in more than 100 countries, primarily in tropical and subtropical regions of Asia, the Pacific, the Americas, Africa, and the Caribbean. The World Health Organization (WHO) estimates 390 million infections per year, with about 96 million presenting clinically, and roughly 500,000 cases progress to severe dengue requiring hospitalization.[1][2]
All age groups can be infected, but children and young adults in endemic areas bear the highest disease burden. Travelers returning from endemic zones are also at risk.
Symptoms
The biphasic fever pattern usually unfolds over 5–7 days, but symptoms can vary. Below is a complete list with brief descriptions.
Phase 1 – Initial Febrile Phase (Days 1‑3)
- High fever: Sudden onset of temperature 38.5‑40 °C (101‑104 °F).
- Severe headache: Often retro‑orbital (behind the eyes).
- Myalgia & arthralgia: Muscle and joint pains; the illness is sometimes called “break‑bone fever.”
- Rash: Maculopapular or morbilliform, may appear on the trunk.
- Nausea, vomiting, or abdominal pain.
- Fatigue and malaise.
- Conjunctival injection: Redness of the eyes without discharge.
Phase 2 – Critical (Defervescence) Phase (Days 4‑6)
- Defervescence: Temperature drops to normal or low‑grade (often 37 °C/98.6 °F) for 24‑48 hours.
- Re‑emergent fever: Second rise in temperature (biphasic pattern) may occur.
- Increased abdominal pain: May signal plasma leakage.
- Persistent vomiting or diarrhea.
- Bleeding tendencies: Petechiae, gum bleeding, epistaxis, easy bruising.
- Warning signs of severe dengue: Rapid pulse, hypotension, cold extremities, lethargy.
Phase 3 – Recovery Phase (Days 7‑10)
- Gradual resolution of fever.
- Improvement of skin rash.
- Return of appetite and energy levels.
- Possible prolonged fatigue for weeks.
Causes and Risk Factors
Dengue virus is transmitted primarily by the bite of infected Aedes aegypti and, to a lesser extent, Aedes albopictus mosquitoes. The virus replicates in the mosquito’s salivary glands and is injected into the human host during feeding.
Primary Causes
- Inoculation of dengue virus via an infected mosquito bite.
- Secondary infection with a different serotype (antibody‑dependent enhancement) can increase severity.
Risk Factors
- Geographic exposure: Living in or traveling to endemic regions.
- Urbanization: Aedes mosquitoes thrive in densely populated areas with standing water.
- Previous dengue infection: Prior exposure to a different serotype raises risk of severe disease.
- Age: Children (<15 years) and young adults are most frequently affected.
- Pregnancy: Associated with higher risk of severe disease and adverse fetal outcomes.
- Comorbidities: Diabetes, hypertension, and immune suppression may worsen prognosis.
Diagnosis
Early recognition is critical because the clinical picture can mimic other febrile illnesses (malaria, chikungunya, Zika). Diagnosis relies on a combination of history, physical examination, and laboratory testing.
Laboratory Tests
- Complete blood count (CBC): Typically shows leukopenia, thrombocytopenia, and hemoconcentration (hematocrit rise) during the critical phase.
- Serum chemistry: Elevated liver enzymes (AST/ALT) and electrolyte disturbances may be present.
- Dengue NS1 antigen test: Detects viral protein 1 from day 1‑7 of illness; high sensitivity (≈85‑90%).
- Reverse transcription polymerase chain reaction (RT‑PCR): Detects viral RNA, most reliable within the first 5 days.
- IgM/IgG serology: IgM appears after day 5, IgG indicates past infection; useful after the acute phase.
Diagnostic Criteria (WHO 2009)
- Fever plus two or more of: nausea/vomiting, rash, aches, leukopenia, or positive tourniquet test.
- Presence of “warning signs” (e.g., abdominal pain, persistent vomiting, mucosal bleeding) classifies the case as dengue with warning signs.
- Severe dengue is diagnosed when plasma leakage, severe bleeding, or organ impairment occurs.
Treatment Options
There is no specific antiviral therapy for dengue; management is supportive and focused on preventing complications.
General Supportive Care
- Fluid management: Oral rehydration solution (ORS) for mild cases; intravenous isotonic fluids (e.g., Ringer’s lactate) during the critical phase to maintain euvolemia.
- Antipyretics: Acetaminophen (paracetamol) 500‑1000 mg every 6 hours; avoid NSAIDs (ibuprofen, aspirin) because of bleeding risk.
- Monitoring: Hourly vitals, strict intake‑output charting, daily hematocrit and platelet count.
Medications
- Analgesia/antipyresis: Acetaminophen only.
- Antiemetics: Ondansetron or metoclopramide if vomiting interferes with oral intake.
- Tranexamic acid: Not routinely recommended; may be considered in severe bleeding under specialist supervision.
Hospital‑Based Interventions (for severe dengue)
- Careful titration of IV fluids guided by hematocrit and urine output.
- Blood component therapy (platelet transfusion, fresh frozen plasma) for major hemorrhage.
- Inotropic support for shock refractory to fluid resuscitation.
Lifestyle & Home Measures
- Rest in a cool, well‑ventilated area.
- Maintain adequate hydration—aim for 2.5‑3 L of fluid per day, adjusted for fever and sweating.
- Use a calibrated thermometer to track fever trends, documenting the biphasic pattern.
Living with Biphasic Fever (Dengue)
Even after the acute phase resolves, many patients experience lingering fatigue and mood changes. Below are practical tips to aid recovery.
- Hydration: Continue ORS or electrolyte drinks for at least a week after fever subsides.
- Nutrition: Eat small, frequent meals rich in proteins, vitamins C & B complex, and potassium (e.g., bananas, papaya, beans).
- Activity pacing: Gradually increase physical activity; avoid strenuous exercise for 2‑3 weeks.
- Sleep hygiene: Aim for 7‑9 hours/night; use a cool room and light blankets.
- Monitoring: Re‑check platelet count and hematocrit 5‑7 days after symptom onset, especially if you had warning signs.
- Psychological support: Persistent fatigue can be frustrating; consider light counseling or support groups.
Prevention
Because dengue is vector‑borne, control measures focus on reducing mosquito exposure.
Personal Protective Measures
- Use EPA‑registered insect repellents containing DEET, picaridin, IR3535, or oil of lemon eucalyptus.
- Wear long‑sleeved shirts and pants, especially during daylight hours when Aedes mosquitoes are most active.
- Sleep under insecticide‑treated mosquito nets if air‑conditioned rooms are unavailable.
Environmental Control
- Eliminate standing water in flower pots, tires, buckets, and water storage containers.
- Apply larvicides (e.g., Bacillus thuringiensis israelensis) to water that cannot be removed.
- Cover water storage tanks with tight‑fitting lids.
- Community clean‑up campaigns and fogging are effective when coordinated by local health authorities.
Vaccination
The WHO‑prequalified Dengvaxia (CYD‑TDV) is a tetravalent live‑attenuated vaccine approved for individuals 9‑45 years old with documented prior dengue infection. It reduces the risk of severe disease but is not recommended for seronegative persons because of a potential increase in severe dengue upon subsequent infection.[3]
Complications
If not recognized early or inadequately managed, dengue can progress to life‑threatening complications.
- Severe dengue (Dengue Hemorrhagic Fever/Dengue Shock Syndrome): Plasma leakage leading to hypovolemic shock, severe bleeding, or organ failure.
- Acute liver failure: Marked transaminase elevations, possible hepatic encephalopathy.
- Acute kidney injury: Resulting from hypoperfusion or rhabdomyolysis.
- Myocarditis and arrhythmias.
- Neurological manifestations: Encephalitis, seizures, Guillain‑Barré syndrome.
- Vertical transmission: May cause intra‑uterine infection, miscarriage, or neonatal dengue.
When to Seek Emergency Care
- Severe abdominal pain or persistent vomiting
- Rapid, weak pulse or low blood pressure (signs of shock)
- Bleeding from gums, nose, or under the skin (large bruises, petechiae)
- Difficulty breathing or severe shortness of breath
- Altered mental status – confusion, drowsiness, or seizures
- Sudden drop in platelet count below 50,000 µL (if known)
- Persistent high fever (>38.5 °C) that does not respond to acetaminophen
Call emergency services (e.g., 911) or go to the nearest hospital with an intensive care unit.
References
- World Health Organization. Dengue and severe dengue. 2023. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue
- Miller, R. et al. Global distribution of dengue. Nat Rev Microbiol. 2022;20(3):152‑163.
- Guzman, M.G., et al. Dengue vaccine: recommendations and considerations. Cleveland Clinic Journal of Medicine. 2021;88(7):453‑461.
- Centers for Disease Control and Prevention. Dengue clinical guidance. 2023. https://www.cdc.gov/dengue/clinical/index.html
- Mayo Clinic. Dengue fever. 2024. https://www.mayoclinic.org/diseases-conditions/dengue-fever/symptoms-causes/syc-20353058